《大行报告》大和上调中生制药(01177.HK)目标价至12元 评级「买入」
大和发表研究报告指,中生制药(01177.HK)管理层预期被纳入国家集中采购的旧有仿制药今年销售可增长逾一成,考虑到新药安罗替尼(Anlotinib)今年首两个月销售收入按年增幅达双位数,预期在国家医保药品目录准入谈判後增长势头已恢复,相信产品今年收入可增至52亿元人民币(2020年42亿元人民币)。
该行又预期,计及公司於科兴疫苗的投资,以及未来将订立更多产品开发、授权等商业合作,估计今年核心盈利可按年增长20%,将目标价由11元升至12元,维持「买入」评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.